Wockhardt has reported results for second quarter ended September 30, 2012.
The company has reported a jump of over six-fold in its net profit at Rs 345.30 crore for the quarter ended September 30, 2012 as compared to Rs 53.80 crore for the same quarter in the previous year. Total income of the company has increased by 5.45% at Rs 604.84 crore for quarter under review as compared to Rs 573.55 crore for the quarter ended September 30, 2011.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
